Cue Biopharma Inc. (NASDAQ: CUE) witnessed a dramatic sell-off in its stock price after the clinical-stage biotechnology firm disclosed the terms of a substantial public equity offering. The announcement, which detailed a significant discount to the prevailing market price, has unsettled investors and driven the share value to a record low.
Strategic Shift and Capital Needs
The capital raise comes at a pivotal moment for the company. Cue Biopharma recently underwent a strategic leadership transition, with new Chief Executive Officer Usman Azam now placing increased emphasis on candidates targeting autoimmune diseases. Despite a challenging year for the stock—which has declined nearly 69% since January—management stated that the proceeds from this offering, combined with existing cash and anticipated payments from its ImmunoScape collaboration, are expected to fund operations into the first quarter of 2027. This extension of the financial runway is intended to support the advancement of its clinical pipeline. The company’s current market capitalization of approximately $27 million, however, highlights the high-risk environment for a clinical-stage biotech.
Details of the Dilutive Financing
On Friday, December 19, 2025, Cue Biopharma confirmed the pricing for its public placement. The company is issuing 35,714,286 shares of common stock at a price of $0.28 per unit. Each unit consists of one share of common stock (or one pre-funded warrant in lieu thereof) and one accompanying warrant to purchase additional stock.
The accompanying warrants provide for the purchase of up to an aggregate of 17,857,143 more shares at an exercise price of $0.30 per share. These warrants are immediately exercisable and will expire five years from the date of issuance. Gross proceeds from the offering, before deducting fees and underwriting discounts, are estimated to be roughly $10 million.
Should investors sell immediately? Or is it worth buying Cue Biopharma?
The market’s reaction was swift and severe. By the close of trading on Friday, Cue Biopharma shares were trading around $0.26, representing a single-day decline of 24.04 percent. The steep discount of the offering price relative to the prior trading level, coupled with the substantial dilution facing existing shareholders, triggered the wave of selling. H.C. Wainwright & Co. is acting as the sole book-running manager for the transaction, which is expected to close on Monday, December 22, 2025.
Market Outlook and Technical Pressure
Investor attention now turns to the official closing of the offering this coming Monday, December 22, 2025. A 30-day option granted to the underwriters to purchase up to an additional 15% of shares (approximately 5.36 million) could supply further liquidity but may also cap any near-term recovery in the stock price.
From a technical perspective, the equity is testing new all-time lows in the $0.24 to $0.26 range. Analyst sentiment remains cautious; several firms have downgraded their ratings to “Sell” following the new issuance and adjusted their price targets accordingly. A key focus for the upcoming trading sessions will be whether the $0.25 level can hold as a psychological support zone.
Ad
Cue Biopharma Stock: Buy or Sell?! New Cue Biopharma Analysis from December 20 delivers the answer:
The latest Cue Biopharma figures speak for themselves: Urgent action needed for Cue Biopharma investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 20.
Cue Biopharma: Buy or sell? Read more here...
